Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Xenoscience Inc

Neither a doctor nor a teaching hospital

Research payments

$1,498,483

168 payments

Through program year 2025, Xenoscience Inc is reported as receiving $1,498,483 in research payments, across 168 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $258,742 22
2024 Research $242,227 18
2023 Research $142,091 35
2022 Research $268,516 34
2021 Research $231,595 21
2020 Research $235,785 14
2019 Research $119,527 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $499,028 58 payments
  2. Biogen, Inc. $229,857 12 payments
  3. Ucb SA $186,852 10 payments
  4. Janssen Research & Development, LLC $153,295 7 payments
  5. Amneal Pharmaceuticals LLC $94,908 23 payments
  6. AbbVie, Inc. $93,094 23 payments
  7. Osmotica Pharmaceutical Corp. $69,794 8 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $58,365 19 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $54,630 5 payments
  10. Novartis Pharmaceuticals Corporation $46,047 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Ocrelizumab RMS High Dose Study $250,563 18 payments
  2. Evaluation of Fenebrutinib in RMS Patients II $190,203 33 payments
  3. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $153,295 7 payments
  4. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $76,820 3 payments
  5. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $69,461 4 payments
  6. A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinson's Disease $69,006 1 payment
  7. A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations $68,978 14 payments
  8. Ocrelizumab PPMS High Dose Study $57,962 6 payments
  9. A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 $56,966 2 payments
  10. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $56,794 12 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $8,831 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record